|

SHR-A2102 for injection Clinical Trials

3 actively recruiting trials

No change since May 2026

Pipeline

Phase 2: 1Phase 3: 1Phase 1/2: 1

Top Sponsors

  • Shanghai Hengrui Pharmaceutical Co., Ltd.2
  • Suzhou Suncadia Biopharmaceuticals Co., Ltd.1

Indications

  • Cancer3
  • Advanced Gynecological Malignancy1
  • Recurrent Cervical Cancer1
  • Metastatic Cervical Cancer1
  • Advanced or Metastatic Non-small Cell Lung Cancer1

Other3 trials

A Study of SHR-A2102 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-based Chemotherapy and PD-(L)1 Inhibitor Treatment Failed Recurrent or Metastatic Cervical Cancer
Phase 3
A Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Non-small Cell Lung Cancer
Phase 1/2
A Trial of SHR-A2102 for Treatment of Advanced Gynecological Malignancy
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.